Ying-Fu Wang1, Yang-Hong Dai1, Chun-Shu Lin1, Hao-Chih Chang1, Po-Chien Shen1, Jen-Fu Yang1, Chih-Weim Hsiang2, Cheng-Hsiang Lo3, Wen-Yen Huang4. 1. Department of Radiation Oncology, Tri-Service General Hospital, National Defense Medical Center, No. 325, Cheng-Gong Rd, Neihu, Taipei, 114, Taiwan. 2. Department of Radiology, Tri-Service General Hospital, National Defense Medical Center, No. 325, Cheng-Gong Rd, Neihu, Taipei, 114, Taiwan. 3. Department of Radiation Oncology, Tri-Service General Hospital, National Defense Medical Center, No. 325, Cheng-Gong Rd, Neihu, Taipei, 114, Taiwan. lsir183@yahoo.com.tw. 4. Department of Radiation Oncology, Tri-Service General Hospital, National Defense Medical Center, No. 325, Cheng-Gong Rd, Neihu, Taipei, 114, Taiwan. hwyyi@yahoo.com.tw.
Abstract
BACKGROUND: Stereotactic body radiotherapy (SBRT) is an emerging modality for hepatocellular carcinoma (HCC). However, there is scant information about its safety and effectiveness in the neoadjuvant setting prior to liver transplantation (LT). We present the clinical outcome and pathologic assessment of SBRT followed by LT for patients with advanced HCC. METHODS: This retrospective study included HCC patients treated with neoadjuvant SBRT prior to LT between 2009 and 2018. Radiographic response and adverse effects, including radiation-induced liver disease (RILD), were evaluated. Pathologic response was assessed by the percentage of tumor necrosis relative to the total tumor volume. Overall survival (OS) and recurrence-free survival (RFS) were calculated using the Kaplan-Meier method. RESULTS: Fourteen patients underwent SBRT for a total of 25 HCC lesions, followed by LT. The median tumor size was 4.45 cm in diameter, and the median prescribed dose was 45 Gy in 5 fractions. SBRT provided significant AFP reduction, 100% infield control, and a 62.5% response rate. The maximum detected toxicity included grade 3 thrombocytopenia and two grade 3-4 hyperbilirubinemia. One patient developed non-classic RILD. Patients were bridged to LT with a median time of 8.4 months after SBRT, and 23.1% of them achieved a complete pathologic response. The median OS and RFS were 37.8 and 18.3 months from the time of LT, respectively. CONCLUSIONS: SBRT provides favorable tumor control and acceptable adverse effects for patients awaiting LT. Further prospective studies to test SBRT as a bridging therapy for LT are feasible.
BACKGROUND: Stereotactic body radiotherapy (SBRT) is an emerging modality for hepatocellular carcinoma (HCC). However, there is scant information about its safety and effectiveness in the neoadjuvant setting prior to liver transplantation (LT). We present the clinical outcome and pathologic assessment of SBRT followed by LT for patients with advanced HCC. METHODS: This retrospective study included HCCpatients treated with neoadjuvant SBRT prior to LT between 2009 and 2018. Radiographic response and adverse effects, including radiation-induced liver disease (RILD), were evaluated. Pathologic response was assessed by the percentage of tumor necrosis relative to the total tumor volume. Overall survival (OS) and recurrence-free survival (RFS) were calculated using the Kaplan-Meier method. RESULTS: Fourteen patients underwent SBRT for a total of 25 HCC lesions, followed by LT. The median tumor size was 4.45 cm in diameter, and the median prescribed dose was 45 Gy in 5 fractions. SBRT provided significant AFP reduction, 100% infield control, and a 62.5% response rate. The maximum detected toxicity included grade 3 thrombocytopenia and two grade 3-4 hyperbilirubinemia. One patient developed non-classic RILD. Patients were bridged to LT with a median time of 8.4 months after SBRT, and 23.1% of them achieved a complete pathologic response. The median OS and RFS were 37.8 and 18.3 months from the time of LT, respectively. CONCLUSIONS: SBRT provides favorable tumor control and acceptable adverse effects for patients awaiting LT. Further prospective studies to test SBRT as a bridging therapy for LT are feasible.
Entities:
Keywords:
Hepatocellular carcinoma; Liver transplantation; Radiotherapy; Stereotactic body radiotherapy
Authors: Ulrike Bauer; Sabine Gerum; Falk Roeder; Stefan Münch; Stephanie E Combs; Alexander B Philipp; Enrico N De Toni; Martha M Kirstein; Arndt Vogel; Carolin Mogler; Bernhard Haller; Jens Neumann; Rickmer F Braren; Marcus R Makowski; Philipp Paprottka; Markus Guba; Fabian Geisler; Roland M Schmid; Andreas Umgelter; Ursula Ehmer Journal: World J Gastroenterol Date: 2021-06-28 Impact factor: 5.742